Cardiff Oncology, Inc. (NASDAQ: CRDF) is a Healthcare company (Biotechnology) with a market capitalization of $66M. The Maz Rating grades it against the other companies in its sector.
Cardiff Oncology, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $0.85, Cardiff Oncology, Inc. trades at 115.9x sales and 2.3x book value. Over the last twelve months it generated about $568129 of revenue and a net loss of $43M. It runs a gross margin of -1579.8%, an operating margin of -7068.2% and a net margin of -6735.2%. It shows return on equity of -111.8%, return on invested capital of -139.3% and a free cash flow yield of -61.7%. On the balance sheet: a debt-to-equity ratio of 0.01 and a current ratio of 4.21. Over the past 52 weeks the share price ranged from $0.71 to $3.31, with a beta of 1.56.
Cardiff Oncology, Inc. does not currently pay a dividend.
15 Wall Street analyst ratings cover the stock: 8 Buy, 6 Hold and 1 Sell, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.